2020
DOI: 10.37757/mr2020.v22.n3.10
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic Scale to Stratify Risk of Intrahospital Death in Patients with Acute Myocardial Infarction with ST Segment Elevation

Abstract: INTRODUCTIONThe scales available to predict death and complications after acute coronary syndrome include angiographic studies and serum biomarkers that are not within reach of services with limited resources. Such services need specifi c and sensitive instruments to evaluate risk using accessible resources and information.OBJECTIVE Develop a scale to estimate and stratify the risk of intrahospital death in patients with acute ST-segment elevation myocardial infarction.METHODS An analytical observational study… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 32 publications
0
3
0
Order By: Relevance
“…APG was shown to be associated with in-hospital outcomes. A study of 667 patients admitted with first STEMI reported that APG ≥11.1 mmol/L was the second-best predictor of in-hospital mortality after cardiac arrest [ 40 ]. Similarly, a study of 1168 Black Africans with ACS [ 41 ] reported that elevated APG was associated with in-hospital mortality at an even lower threshold (>7.8 mmol/L).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…APG was shown to be associated with in-hospital outcomes. A study of 667 patients admitted with first STEMI reported that APG ≥11.1 mmol/L was the second-best predictor of in-hospital mortality after cardiac arrest [ 40 ]. Similarly, a study of 1168 Black Africans with ACS [ 41 ] reported that elevated APG was associated with in-hospital mortality at an even lower threshold (>7.8 mmol/L).…”
Section: Resultsmentioning
confidence: 99%
“… Biomarker Details Outcome(s) Follow-up n Predictor/Cut-Off Value Risk [95% CI] Ref. APG STEMI/NSTEMI + PCI; no known DM MACE: death, MI, HF, or stroke 180 days 5309 7.0–11.0 mmol/L vs. <6.1 mmol/L (126–198 mg/dL vs. <110 mg/dL) OR 1.62 [1.14–2.29] [ 42 ] >11 mmol/L vs. <6.1 mmol/L (>198 mg/dL vs. <110 mg/dL) OR 3.59 [1.99–6.50] STEMI/NSTEMI + PCI; known DM Higher OR 2.42 [1.71–3.42] ACS ± DM (Black Africans) Mortality In-hospital 1168 >7.8 mmol/L (>140 mg/dL) HR 2.33 [1.44–3.77] [ 41 ] ACS, no DM (Black Africans) 836 HR 3.12 [1.72–5.68] First STEMI, no PCI Mortality In-hospital 667 ≥11.1 mmol/L (≥200 mg/dL) OR 2.62 [1.74–3.93] [ 40 ] Higher HR 3.17 [2.46–4.09] ...…”
Section: Resultsmentioning
confidence: 99%
“…Clinical studies have found that there are two categories of outcomes faced by nerve cells corresponding to ACI, namely, cell necrosis and apoptosis, in which cell necrosis corresponds to neurons in a hypoxic state for up to 5 min, and apoptosis to ischemic penumbra cells, with lagging death time. According to the current findings, it is known that the pathological process of ACI includes loss of ionic balance, energy failure, activation of free radicals, and glial cell activation, so the later the intervention is initiated, the greater the degree of neurocellular pathophysiological alterations at the time of blood perfusion recovery [ 24 ]. The study findings showed that the time window was positively correlative with the mRS score, namely, the larger the time window, the higher the mRS score and the worse the clinical prognosis of patients.…”
Section: Discussionmentioning
confidence: 99%